Brain Imaging and Retreatment Study of Persistent Lyme Disease

Lyme Disease Clinical Trial

Official title:

PET and MRI Imaging of Persistent Lyme Encephalopathy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00037479
• Other study ID #: R01NS038636
• Status: Completed
• Phase: Phase 2
• First received: May 17, 2002
• Last updated: December 6, 2005
• Start date: December 1999

Study information

• Verified date: December 2005
• Source: National Institute of Neurological Disorders and Stroke (NINDS)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether patients with persistent memory problems after Lyme disease benefit from an additional longer course of IV antibiotic therapy; to use modern brain imaging technology to determine whether the problem in the central nervous system is primarily one of poor blood flow or one of impaired nerve cell functioning; and to try to identify biological markers prior to treatment that will identify patients who are more or less likely to respond to the study treatment.

Description:

Some people with a history of Lyme disease continue to have problems despite having received “textbook duration” antibiotic therapy. When memory, attention, or thinking problems persist, the syndrome is called persistent Lyme disease (PLD). This study seeks to answer critical scientific questions about the treatment and cause of PLD symptoms.

This 24-week treatment study will evaluate each patient’s response to treatment using neuropsychological testing and state-of-the-art brain imaging. The brain tests include neuropsychological testing of memory and attention, brain imaging (MRI and PET scans) to look at blood flow in the brain and nerve cell structure and metabolism, a neurological exam, and studies of the fluid that surrounds the brain (cerebrospinal fluid). The treatment involves 10 weeks of either intravenous antibiotic called ceftriaxone (also known as Rocephin) or intravenous placebo (inactive substance). After the first visit to Columbia Presbyterian Medical Center, the remaining treatments will be done in the patient’s home. Patients will be screened over the phone and in person to confirm study eligibility.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

Eligible participants must:

• Be 18-65 years old

• Have persistent problems with memory, verbal fluency, or attention after having contracted Lyme disease.

• Be able to travel to New York for 4-5 evaluations over the course of one year. Travel costs for participants in need may be partially or fully reimbursable.

• Have had a history of well-documented Lyme disease using the CDC's clinical criteria and a current positive IgG Western blot or PCR.

• Have received, at some point in the past at least 3 weeks of IV antibiotic therapy for Lyme disease.

Exclusion Criteria:

Ineligible from participation are people with the following:

• Other major medical or neurologic problems

• Smoke more than 10 cigarettes a day

• Uncontrolled high blood pressure

• Allergy to ceftriaxone (Rocephin)

• History of marked cocaine abuse

Twenty healthy subjects are also being sought for the study.

Study Design

Allocation: Randomized, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lyme Disease
• Lyme Neuroborreliosis

Intervention

Drug:
• ceftriaxone

Locations

Country	Name	City	State
United States	Columbia Presbyterian Medical Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

External Links

•   Columbia's Lyme disease research studies website